Lung Cancer News and Research

Latest Lung Cancer News and Research

New nicotine addiction mechanism revealed

A new discovery has shown why some people cannot give up tobacco and may lead to new anti-smoking treatments. The researchers have found a brain pathway which when defective leads to an uncontrollable desire to smoke. This is a “sub-unit” of a receptor protein sensitive to nicotine.

31 Jan 2011

$61 million anti-tobacco campaign launched to prevent lung cancer

The Australian Federal Government is backing a $61 million advertising campaign to stop smoking. This is the nation’s biggest anti-tobacco campaign. The message is graphic and simple: every cigarette brings cancer closer. Health groups have backed the campaign but advertising industry experts say the public has become increasingly immune to scare campaigns.

31 Jan 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib in non-small cell lung cancer at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

28 Jan 2011

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Sanofi-aventis and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival

28 Jan 2011

NHS reforms & proposed spending questioned

According to John Appleby, Chief Economist at the King’s Fund, deaths from heart attacks and cancer in the UK are falling despite lower spending on health than in countries such as France. This, he said calls attention to the Government’s claim that poor outcomes justify a £1.4 billion restructuring of the NHS that will pass control of budgets from managers to GPs. He said, “Comparing health outcomes across countries is complex and not simply down to healthcare spending, but these trends must challenge one of the government’s key justifications for reforming the NHS.”

27 Jan 2011

ASCO urges physicians, medical schools to improve quality of life for people with cancer

The American Society of Clinical Oncology today called on physicians, medical schools, insurers, and others to help improve quality of life for people with advanced cancer.

25 Jan 2011

ASU Biodesign Institute hosts international research consortium on early detection of lung cancer

To address the latest issues on the early detection of lung cancer, the Biodesign Institute at Arizona State University will host an international research consortium in Scottsdale, Ariz., Feb. 25-26.

25 Jan 2011

Breast and lung cancer: Shared risk and treatment

New research has shown that women who are heavy smokers before menopause, especially prior to giving birth, may significantly increase their risk of developing breast cancer. In the US study looking at almost 150,000 women from the Nurses’ Health Study; it was found that breast cancer rates increased with higher levels of smoking among younger age groups. The study appeared in the journal Archives of Internal Medicine.

24 Jan 2011

Blocking rogue gene may stop cancer spread: Study

In a new breakthrough British scientists have discovered a “rogue gene” which helps cancer spread around the body and add that this could mean specific therapy, if developed against the gene, could stop cancer spread.

24 Jan 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

Healthcare workers can help improve quality of life for end of life patients

Healthcare workers can most directly affect quality of life (QOL) of patients with advanced stage lung cancer by helping manage symptoms such as pain, lack of energy, shortness of breath, coughing, difficulty sleeping and dry mouth, according to a study recently published in the journal Oncology Nursing Forum.

24 Jan 2011

Tamoxifen may reduce individual's risk of death from lung cancer: New study

A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual's risk of death from lung cancer.

24 Jan 2011

Britain’s cancer rates improve while Denmark scores poorly

It appears that warnings regarding dangers of smoking appear to be having an effect with the UK placed in 22nd position in a world league of highest cancer rates. Figures show that for men, 280 cases per 100,000 people, is 33rd in the world, with France the highest. The rate for British women, however, is 260.5 per 100,000 – the world’s 12th highest, with Denmark top. The UK breast cancer rate for women, which is just over 89, ranks 11th.

23 Jan 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California.

21 Jan 2011

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced that Teva Pharmaceutical Industries Limited (Teva) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share.

21 Jan 2011

COPD patients on LTOT may face high risk of death from cardiovascular disease

Patients suffering from chronic obstructive pulmonary disease who are on long-term oxygen therapy have more to worry about than breathing difficulties. According to a new study by researchers in Sweden, COPD patients on LTOT today face an increased risk of death from cardiovascular disease and other non-respiratory ailments.

20 Jan 2011

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinapar™ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).

20 Jan 2011

FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review

ADVENTRX Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011 for the review of the Exelbine (ANX-530) New Drug Application (NDA).

20 Jan 2011

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

19 Jan 2011

Lung Cancer News and Research

Latest Lung Cancer News and Research

New nicotine addiction mechanism revealed

$61 million anti-tobacco campaign launched to prevent lung cancer

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

NHS reforms & proposed spending questioned

ASCO urges physicians, medical schools to improve quality of life for people with cancer

ASU Biodesign Institute hosts international research consortium on early detection of lung cancer

Breast and lung cancer: Shared risk and treatment

Blocking rogue gene may stop cancer spread: Study

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

Healthcare workers can help improve quality of life for end of life patients

Tamoxifen may reduce individual's risk of death from lung cancer: New study

Britain’s cancer rates improve while Denmark scores poorly

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

COPD patients on LTOT may face high risk of death from cardiovascular disease

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

The ultimate guide to lung research tools and protocols eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in